Dendrite Signs Major Pharmaceutical Client Product Upgrade.

Business Editors/Health & Medical Writers

MORRISTOWN, N.J.--(BUSINESS WIRE)--July 17, 2001

Dendrite International (NASDAQ/NMS: DRTE) today announced that it has signed a major customer product upgrade contract. The contract, which has a minor impact on second-quarter revenue, will be largely recognized in subsequent quarters based on customer implementation schedules.

Dendrite's existing customer has taken the newest WebForce(TM), with embedded ForceAnalyzer(TM) and the Dendrite palm top solution ForceMobile(TM) companion, on a global basis.

"We are proud to have successfully closed this agreement and to be part of our customer's ongoing growth," said Dendrite Chairman and CEO John Bailye.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

The foregoing contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The statements may be identified by such forward-looking terminology as "expect," "believe," "may," "will," "intend," "plan," and similar statements or variations. Such forward-looking statements are based on our current estimates and assumptions and involve certain significant risks and uncertainties, including: risks associated with and dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy selling cycles, product implementation cycles, customer budget cycles, and timing of revenue recognition; dependence on major customers; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; retention of key senior managers; and unique characteristics of the consumer packaged goods industry. Other important factors that should be considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements.